The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
Primary Purpose
Aspergillosis, Cystic Fibrosis
Status
Terminated
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
PC945
Sponsored by
About this trial
This is an interventional treatment trial for Aspergillosis
Eligibility Criteria
Inclusion Criteria:
- Subject must be male or female, aged 18 years inclusive or older (at the time of consent).
- Subject must be willing and able to adhere to the restrictions and prohibitions required by this protocol.
- Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose and requirements of the study and that they are willing to participate.
- A confirmed diagnosis of CF by standard criteria.
- Subject is able to produce sputum.
- A history of persistently positive A. fumigatus sputum cultures from at least 2 sputum samples in the last year, the most recent of which must have been within the last 6 months.
- Subject must have a positive sputum fungal culture at screening with one or more colonies of A. fumigatus detected using a modified standard approach.
Exclusion Criteria:
- Any other disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in a clinical trial.
- Is taking inhaled amphotericin B or has taken it within 7 weeks of Day 1.
- Is taking systemic steroid treatment or has taken it within 4 weeks of Day 1. Subjects considered to be stable on a systemic steroid dose of <15 mg for at least a month will not be excluded.
- Is taking systemic antifungal treatment (intravenous, oral or inhaled) or has received antifungal therapy (intravenous, oral or inhaled) within 6 weeks of Day 1.
- If female, the subject is pregnant (e.g., has a positive serum β human chorionic gonadotropin (β-hCG) at screening or a positive urinary pregnancy test pre-dose on Day 1), lactating or breast feeding.
- Any respiratory exacerbation within 2 weeks of the start of the study.
- Any upper respiratory tract infection or signs or symptoms thereof within 2 weeks prior to dosing.
- Positive culture for Mycobacterium abscessus within 12 months before screening or between screening and baseline, or currently receiving treatment for Mycobacterium abscessus.
- Has chronic, active hepatitis or a positive hepatitis B surface antigen or positive hepatitis C antibody result at screening.
- Is taking antiretroviral protease inhibitor therapy.
- Allergy to any of the active or inactive ingredients in the study medication.
- History of drug (or other) allergy or intolerance that, in the opinion of the Investigator or Pulmocide Medical Monitor, would contraindicate their participation.
- Clinically significant haemoptysis (>200 mL per episode) within 90 days before screening.
- Subject is mentally or legally incapacitated. 19 July 2018 CONFIDENTIAL Page 27 of 58 Pulmocide Ltd Clinical Protocol PC_ASP_003
- Subject is employed or is a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study.
- Any other reason that the Investigator considers makes the subject unsuitable to participate.
Sites / Locations
- Royal Brompton Hospital
- Northwest Lung Research Centre
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PC945
Arm Description
PC945 5mg once daily
Outcomes
Primary Outcome Measures
Adverse events (AEs)
Proportion of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at lease once post dose
Proportion of participants who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose
Proportion of participants who meet the markedly abnormal criteria for vital signs assessment at lease once post dose
Predicted post bronchodilator forced expiratory volume in 1 second (FEV1) values
Forced vital capacity (FVC) values
Peak expiratory flow rate values (PEFR)
Maximum expiratory flow values (MEF25-75)
Breathlessness visual analogue scale rating, change over time
Symptom severity rated from "Best ever" to "Worst possible"
Cough visual analogue scale rating, change over time
Symptom severity rated from "Best ever" to "Worst possible"
Area under the curve from time 0 to 2 h post-dose (AUC0-2)
Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable
Maximum plasma concentration
Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable
Concentration at the end of the dosage interval (Ctrough)
Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable
Secondary Outcome Measures
Change in the number of sputum A. fumigatus colony forming units (CFU)
A. fumigatus status (presence or absence) in subjects with a baseline A. fumigatus-positive sputum culture
Change in sputum A. fumigatus measured by quantitative polymerase chain reaction (qPCR)
Change in the serum concentration of A. fumigatus-specific immunoglobulins G (IgG)
Change in serum Total immunoglobulin E (IgE) levels
Change in serum Aspergillus-specific IgE levels
Correlation between A. fumigatus measured by qPCR and clinical response
Cystic Fibrosis Questionnaire - Revised (CFQ-R) score
Sputum consistency, including presence of blood
Categorical variable
Sputum colour
Categorical variable using standardised colour chart.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03870841
Brief Title
The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
Official Title
An Open-label Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Inhaled PC945 in Adult Cystic Fibrosis (CF) Patients With Persistent Pulmonary Aspergillus Fumigatus Infection
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Terminated
Why Stopped
The study is being terminated early as a result of the coronavirus (COVID-19) outbreak.
Study Start Date
April 3, 2019 (Actual)
Primary Completion Date
June 1, 2020 (Actual)
Study Completion Date
June 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pulmocide Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study tests the effects of an experimental drug PC945 in people with cystic fibrosis whose lungs are infected by the fungus Aspergillus fumigatus.
PC945 may be useful in treating patients infected with Aspergillus fumigatus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will continue to be treated with their usual cystic fibrosis treatment and will also receive PC945. The amount of fungus in the patients' phlegm will be measured over the course of the study. The study will take place at multiple sites in UK and will include approximately 18 participants. The maximum study duration will be about 16 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aspergillosis, Cystic Fibrosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PC945
Arm Type
Experimental
Arm Description
PC945 5mg once daily
Intervention Type
Drug
Intervention Name(s)
PC945
Intervention Description
PC945, nebulized
Primary Outcome Measure Information:
Title
Adverse events (AEs)
Time Frame
Baseline to Day 84
Title
Proportion of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at lease once post dose
Time Frame
Baseline to Day 84
Title
Proportion of participants who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose
Time Frame
Baseline to Day 84
Title
Proportion of participants who meet the markedly abnormal criteria for vital signs assessment at lease once post dose
Time Frame
Baseline to Day 84
Title
Predicted post bronchodilator forced expiratory volume in 1 second (FEV1) values
Time Frame
Baseline to Day 84
Title
Forced vital capacity (FVC) values
Time Frame
Baseline to Day 84
Title
Peak expiratory flow rate values (PEFR)
Time Frame
Baseline to Day 84
Title
Maximum expiratory flow values (MEF25-75)
Time Frame
Baseline to Day 84
Title
Breathlessness visual analogue scale rating, change over time
Description
Symptom severity rated from "Best ever" to "Worst possible"
Time Frame
Baseline to Day 84
Title
Cough visual analogue scale rating, change over time
Description
Symptom severity rated from "Best ever" to "Worst possible"
Time Frame
Baseline to Day 84
Title
Area under the curve from time 0 to 2 h post-dose (AUC0-2)
Description
Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable
Time Frame
Baseline to Day 84
Title
Maximum plasma concentration
Description
Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable
Time Frame
Baseline to Day 84
Title
Concentration at the end of the dosage interval (Ctrough)
Description
Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable
Time Frame
Baseline to Day 84
Secondary Outcome Measure Information:
Title
Change in the number of sputum A. fumigatus colony forming units (CFU)
Time Frame
Baseline to Day 84
Title
A. fumigatus status (presence or absence) in subjects with a baseline A. fumigatus-positive sputum culture
Time Frame
Day 1 to Day 84
Title
Change in sputum A. fumigatus measured by quantitative polymerase chain reaction (qPCR)
Time Frame
Baseline to Day 84
Title
Change in the serum concentration of A. fumigatus-specific immunoglobulins G (IgG)
Time Frame
Baseline to Day 84
Title
Change in serum Total immunoglobulin E (IgE) levels
Time Frame
Baseline to Day 84
Title
Change in serum Aspergillus-specific IgE levels
Time Frame
Baseline to Day 84
Title
Correlation between A. fumigatus measured by qPCR and clinical response
Time Frame
Baseline to Day 84
Title
Cystic Fibrosis Questionnaire - Revised (CFQ-R) score
Time Frame
Baseline to Day 84
Title
Sputum consistency, including presence of blood
Description
Categorical variable
Time Frame
Baseline to Day 84
Title
Sputum colour
Description
Categorical variable using standardised colour chart.
Time Frame
Baseline to Day 84
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject must be male or female, aged 18 years inclusive or older (at the time of consent).
Subject must be willing and able to adhere to the restrictions and prohibitions required by this protocol.
Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose and requirements of the study and that they are willing to participate.
A confirmed diagnosis of CF by standard criteria.
Subject is able to produce sputum.
A history of persistently positive A. fumigatus sputum cultures from at least 2 sputum samples in the last year, the most recent of which must have been within the last 6 months.
Subject must have a positive sputum fungal culture at screening with one or more colonies of A. fumigatus detected using a modified standard approach.
Exclusion Criteria:
Any other disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in a clinical trial.
Is taking inhaled amphotericin B or has taken it within 7 weeks of Day 1.
Is taking systemic steroid treatment or has taken it within 4 weeks of Day 1. Subjects considered to be stable on a systemic steroid dose of <15 mg for at least a month will not be excluded.
Is taking systemic antifungal treatment (intravenous, oral or inhaled) or has received antifungal therapy (intravenous, oral or inhaled) within 6 weeks of Day 1.
If female, the subject is pregnant (e.g., has a positive serum β human chorionic gonadotropin (β-hCG) at screening or a positive urinary pregnancy test pre-dose on Day 1), lactating or breast feeding.
Any respiratory exacerbation within 2 weeks of the start of the study.
Any upper respiratory tract infection or signs or symptoms thereof within 2 weeks prior to dosing.
Positive culture for Mycobacterium abscessus within 12 months before screening or between screening and baseline, or currently receiving treatment for Mycobacterium abscessus.
Has chronic, active hepatitis or a positive hepatitis B surface antigen or positive hepatitis C antibody result at screening.
Is taking antiretroviral protease inhibitor therapy.
Allergy to any of the active or inactive ingredients in the study medication.
History of drug (or other) allergy or intolerance that, in the opinion of the Investigator or Pulmocide Medical Monitor, would contraindicate their participation.
Clinically significant haemoptysis (>200 mL per episode) within 90 days before screening.
Subject is mentally or legally incapacitated. 19 July 2018 CONFIDENTIAL Page 27 of 58 Pulmocide Ltd Clinical Protocol PC_ASP_003
Subject is employed or is a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study.
Any other reason that the Investigator considers makes the subject unsuitable to participate.
Facility Information:
Facility Name
Royal Brompton Hospital
City
London
ZIP/Postal Code
SW3 6NP
Country
United Kingdom
Facility Name
Northwest Lung Research Centre
City
Manchester
ZIP/Postal Code
M23 9LT
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
We'll reach out to this number within 24 hrs